A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad564 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Kayvan Zainabadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Health, Weill Cornell Medicine, NewYork, New York. Hauptthemen laut MEDLINE: Antitubercular Agents, Linezolid, Clofazimine, Diarylquinolines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Global Health Fellowship, FIC NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
In 2018 the World Health Organization recommended a switch to an all oral bedaquiline-based second-line regimen for treatment of drug-resistant tuberculosis (DR-TB). How these new second-line regimens fare in comparison to first-line regimens for treatment of drug-sensitive tuberculosis (DS-TB) is not well known.
Methods
In this study, we contemporaneously enrolled subjects with DS-TB (n = 31) or DR-TB (n = 23) and assessed their response to therapy with first-line (rifampin, isoniazid, ethambutol, pyrazinamide) or second-line (bedaquiline, pyrazinamide, levofloxacin, linezolid, clofazimine) regimens, respectively.
Results
We found that the early bactericidal activity of first- and second-line regimens was similar during the first 2 weeks of therapy as determined by BACTEC MGIT, colony-forming units, and a liquid limiting dilution assay capable of detecting differentially detectable/culturable Mycobacterium tuberculosis. Furthermore, an identical percentage (77.8%) of subjects from the DS-TB and DR-TB cohorts converted to culture negative after 2 months of therapy.
Conclusions
Despite presenting with more advanced disease at time of treatment, subjects with DR-TB receiving an all oral bedaquiline-based second-line treatment regimen displayed a similar microbiological response to therapy as subjects with DS-TB receiving a first-line treatment regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Global Health, Weill Cornell Medicine, NewYork, New York.
- Les Centres GHESKIO, Port-au-Prince, Haiti.
- Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York.
ORCID-Profile: Kayvan Zainabadi
Förderung
- Global Health Fellowship
- FIC NIH HHS
- NIH HHS
- NCATS NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- Fogarty International Center
Zitieren
APA
Zainabadi, K., Vilbrun, S. C., Mathurin, L. D., Walsh, K. F., Pape, J. W., Fitzgerald, D. W., & Lee, M. H. (2024). A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad564
Vancouver
Zainabadi K, Vilbrun SC, Mathurin LD, Walsh KF, Pape JW, Fitzgerald DW, et al. A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad564
BibTeX
@article{Zainabadi2024,
author = {Zainabadi, Kayvan and Vilbrun, Stalz Charles and Mathurin, Laurent Daniel and Walsh, Kathleen Frances and Pape, Jean William and Fitzgerald, Daniel W and Lee, Myung Hee},
title = {A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad564}
}
EUVIMED